EUVIMEDEUVIMED entdecken
Open Access

Long‐term outcome of tacrolimus‐based immunosuppressive treatment for patients with paediatric‐onset lupus nephritis

Hiroshi Tanaka iD, Tomomi Aizawa iD, Morito Endo

Nephrology · 2024

DOI: 10.1111/nep.14406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology, 2024. Verfasst von Hiroshi Tanaka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Faculty of Health and Medical Care, Hachinohe Gakuin University, Hachinohe, Japan. Hauptthemen laut MEDLINE: Lupus Nephritis, Immunosuppressive Agents, Tacrolimus, Glomerular Filtration Rate. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We have previously reported the mid‐term efficacy and safety of tacrolimus (Tac)‐based immunosuppressive therapy in such patients, and herein, we aimed to determine their long‐term outcomes (over 10 years).

Methods

We retrospectively evaluate the data of 13 consecutive patients with biopsy‐proven long‐standing LN who underwent a long‐term Tac‐based treatment regimen. Tac was administered once daily at a dose of 3 mg as reinduction or maintenance treatment. Treatment outcomes were defined using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), urinary protein/creatinine ratio (Up/cr), serum creatinine, estimated glomerular filtration rate (eGFR) and serological lupus markers (complement C3, complement hemolytic activity [CH 50], and anti‐dsDNA antibody titre), and the concomitantly administered prednisolone (PDN) dose. Data on clinical parameters and serological lupus activity were collected annually from each patient throughout the study period.

Results

The patients' baseline characteristics at the treatment initiation were as follows: mean age, 18 years; Up/cr, 0.63 ± 0.69; serum C3 level, 57.2 ± 22.4 mg/dL (normal range, 79–152 mg/dL); CH50, 27.9 ± 15.7 U/mL (normal range, 23.0–46.0 U/mL); serum anti‐dsDNA antibody titre, 111.7 ± 123.4 IU/mL (normal range,

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisImmunosuppressive AgentsTacrolimusGlomerular Filtration RateComplement C3HumansFemaleRetrospective StudiesMaleAdolescentTreatment OutcomeTime FactorsChildBiomarkersAntibodies, AntinuclearYoung AdultAge of OnsetCreatininePrednisoloneComplement Hemolytic Activity AssayProteinuriaDrug Therapy, CombinationRemission Induction

Stichwörter der Autor:innen

long‐term immunosuppressive therapylong‐term outcomelupus nephritispaediatric‐onset casestacrolimus

Substanzen

Immunosuppressive AgentsTacrolimusComplement C3BiomarkersAntibodies, AntinuclearC3 protein, humanCreatininePrednisoloneanti-dsDNA autoantibody

Autor:innen und Institutionen

  • Department of Nursing, Faculty of Health and Medical Care, Hachinohe Gakuin University, Hachinohe, Japan.
  • Department of School Health Science, Hirosaki University Faculty of Education, Hirosaki, Japan.
  • Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan.
  • Niji-iro Children's Clinic, Hirosaki, Japan.

ORCID-Profile: Hiroshi Tanaka, Tomomi Aizawa

Zitieren

APA

Tanaka, H., Aizawa, T., & Endo, M. (2024). Long‐term outcome of tacrolimus‐based immunosuppressive treatment for patients with paediatric‐onset lupus nephritis. Nephrology. https://doi.org/10.1111/nep.14406

Vancouver

Tanaka H, Aizawa T, Endo M. Long‐term outcome of tacrolimus‐based immunosuppressive treatment for patients with paediatric‐onset lupus nephritis. Nephrology. 2024. doi:10.1111/nep.14406

BibTeX
@article{Tanaka2024,
  author = {Tanaka, Hiroshi and Aizawa, Tomomi and Endo, Morito},
  title = {Long‐term outcome of tacrolimus‐based immunosuppressive treatment for patients with paediatric‐onset lupus nephritis},
  journal = {Nephrology},
  year = {2024},
  doi = {10.1111/nep.14406}
}
Kostenlos starten →